Vimian Group has signed an agreement to develop new vaccines for allergy and atopic dermatitis together with Angany, a Canadian biotechnology company focused on the development of novel bioparticle-based vaccines.
Read MoreAngany Inc., announces today that it has entered into a partnering agreement with Dr. Wayne Shreffler, MD, PhD, Chief, Division of Pediatric Allergy & Immunology and Director of the Food Allergy Center at Massachusetts General Hospital and MassGeneral Hospital for Children, for a comprehensive series of preclinical studies of Angany’s peanut allergy biologic candidate BP/AH-01.
Read MoreQUEBEC CITY and AUSTIN, Texas, March 24, 2021 /CNW Telbec/ - Dr Louis-Philippe Vézina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.
Read More